“We are continuing with the study because we just wanted to have more events and particularly have additional flu B type of events, which were scarce in the U.S. part of the trial. And we look forward to update you, hopefully, be able to conclude the study later this year.”

In context

“tner, does dilute that product from an operating margin perspective. So a mix adjusted, you should see us back to those levels over time. But obviously, as we cycle into ‘24, we’ll give you a lot more clarity on all the puts and takes as we integrate Seagen, as we roll forward from a COVID franchise perspective, how that looks as well as all the developments that we have coming out the pipeline at this point in time. Dr. Albert Bourla: Thank you, David. Mikael mRNA flu. Dr. Mikael Dolsten: Yes. First, the totality of experience we have with mRNA for flu makes me very encouraged that this will be new modality as it was for COVID but now for flu, that engages two mechanisms, the B-cells and the T-cell that we should aspire for, having better efficacy than what we have seen with the old flu. We are continuing with the study because we just wanted to have more events and particularly have additional flu B type of events, which were scarce in the U.S. part of the trial. And we look forward to update you, hopefully, be able to conclude the study later this year. But we also are putting mitigations as adding immunogenicity studies that can be supplementary for getting a total good data package of activity against flu A and flu B. But as I said, I remain very optimistic that the mRNA is going to be the next important platform to deal with flu. Operator: Next, we have Chris Shibutani with Goldman Sachs. Chris Shibutani: Two questions, if I may. On the potential enterprise-wide cost program, you would have some opportunity outside of the COVID programs to consider. Can you help us with the relative weighting potentially of R&D versus SG&A or some other component of that? And I ask that in part because you’ve announced some changes, for instance, in kind of the structure at the top tier of management of the R&D with the anticipation of the oncology in”